Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2019

View Archived Issues

Meta-analysis reveals universally altered genes in early AD

New cholesterol target works independently of LDL receptor

Celyad opens enrollment in phase I trial of CYAD-1 for relapsed/refractory AML or MDS

Akari announces trial design for pivotal phase III study of nomacopan in pediatric HSCT-TMA

BiomX completes enrollment in cosmetic clinical study of BX-001 in acne-prone skin

Funding supports LUNAC-led project to develop next-generation anticoagulant

Neurocrine Biosciences and Xenon collaborate to develop first-in-class treatments for epilepsy

Noxopharm announces promising data from DARRT-1 study of Veyonda in prostate cancer

Seattle Genetics, Astellas, Merck & Co. collaborate to study enfortumab + Keytruda in bladder cancer

Phase IIa study of masupirdine in moderate Alzheimer's disease misses primary endpoint

Novel acute challenge mouse model to assess malaria T-cell vaccine antigens in mice

First report of a schistosome target activated by schistosomes

Phase II results for tislelizumab plus chemotherapy in GC/GEJC and ESCC

SHR-1210 plus apatinib as promising first-line treatment for advanced lung squamous carcinoma

Gilead identifies new Mcl-1 inhibitors

New Bruton tyrosine kinase inhibitors discovered at Biogen

Novo Nordisk patents melanocortin MC4 receptor agonists

Arbutus Biopharma discloses anti-HBV/HDV compounds

Nitric oxide production enhancers identified at Gurus Biopharm

One-year data reported for clinical trial of Pfs230D1M-EPA/AS01 malaria vaccination regimen

Enterotoxigenic E. coli vaccine Etvax in children and infants from Bangladesh: phase I/II results

Darobactin, new antibiotic against Gram-negative pathogens from Photorhabdus nematode symbionts

TAF1 is crucial for AML1-ETO-driven leukemogenesis

Dosing begins in phase I study of UCART-22 in relapsed/refractory B-ALL

OSE-127 phase I data pave way for phase II studies in ulcerative colitis and Sjogren's syndrome

NantKwest reports first safety data from phase I trial of PD-L1 t-haNK in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...